Head to Head Analysis: ENDRA Life Sciences (NASDAQ:NDRA) and Paradigm Medical Industries (OTCMKTS:PDMI)

ENDRA Life Sciences (NASDAQ:NDRA) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares ENDRA Life Sciences and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-397.71%	-190.73%
Paradigm Medical Industries	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for ENDRA Life Sciences and Paradigm Medical Industries, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1	0	1	0	2.00
Paradigm Medical Industries	0	0	0	0	0.00

ENDRA Life Sciences currently has a consensus price target of $30.00, indicating a potential upside of 446.95%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe ENDRA Life Sciences is more favorable than Paradigm Medical Industries.

Risk and Volatility

ENDRA Life Sciences has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Paradigm Medical Industries has a beta of -1.65, suggesting that its stock price is 265% less volatile than the S&P 500.

Institutional and Insider Ownership

1.2% of ENDRA Life Sciences shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ENDRA Life Sciences and Paradigm Medical Industries”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03 million	($8.92)	-0.61
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

Summary

ENDRA Life Sciences beats Paradigm Medical Industries on 5 of the 8 factors compared between the two stocks.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.